Vertaling van "cost-effectiveness of bupropion " (Frans → Nederlands) :

36. Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ et al. The clinical effectiveness and cost-effectiveness of Bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation.
36. Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation.

MeSH : Smoking Cessation ; Nicotine / therapy, drug therapy ; Bupropion ; Antidepressive Agents ; Behavior Therapy ; Counseling ; Cost-Benefit Analysis NLM classification : WM 290
MeSH : Smoking Cessation ; Nicotine / therapy, drug therapy ; Bupropion ; Nortriptyline ; Antidepressive Agents ; Behavior Therapy ; Counseling ; Cost-Benefit Analysis NLM classification : WM 290

40. Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey S et al. Effectiveness of Bupropion sustained release for smoking cessation in a health care setting: a randomized trial.
40. Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey S et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial.

39. Hatsukami DK, Rennard S, Patel MK, Kotlyar M, Malcolm R, Nides MA et al. Effects of sustained-release Bupropion among persons interested in reducing but not quitting smoking.
39. Hatsukami DK, Rennard S, Patel MK, Kotlyar M, Malcolm R, Nides MA et al. Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking.

In this trial, the effect of Bupropion was not significant compared to placebo (p=0,50).
In this trial, the effect of bupropion was not significant compared to placebo (p=0,50).

Van Den Bruel A, Cleemput I, Van Linden A, Schoefs D, Ramaekers D, Bonneux L. Effectiveness and cost-effectiveness of smoking cessation strategies.
Effectiveness and cost-effectiveness of smoking cessation strategies.

Aliment Pharamcol Ther 2009; 29:55-68. van Marrewijk C, Mujakovic S, Fransen G et al. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): primary-care-based randomised controlled trial.
Aliment Pharamcol Ther 2009; 29:55-68. Numans ME, de Wit NJ, Dirven JAM et al. NHG Standaard Maagklachten, tweede herziening.

61. Coleman RW, Rodondi LC et al : Cost-effectiveness of prospective and continuous antibiotic control : expérience et thé Palo Alto Veterans Affairs Médical Center from 1987 to 1989.
61. Coleman RW, Rodondi LC et al: Cost-effectiveness of prospective and continuous antibiotic control: experience at the Palo Alto Veterans Affairs Medical Center from 1987 to 1989.

hospital: what have we learned?J Hosp Infect 2001; 47(1):9-18 43 Kunori T, Cookson B, Roberts JA et al. Cost-effectiveness of different MRSA screening methods.
hospital: what have we learned?J Hosp Infect 2001; 47(1):9-18 44 Kunori T, Cookson B, Roberts JA et al. Cost-effectiveness of different MRSA screening methods.

Conformément aux standards du NICE, les résultats ont été relativement défavorables et " le Comité a conclu que l'ICER (incremental cost-effectiveness ratio – ratio cout efficacité incrémental) le plus plausible du bevacizumab plus paclitaxel versus du paclitaxel toutes les semaines se situait entre £110,000 et £259,000 par QALY gagné”.
Volgens de NICE normen waren de resultaten relatief ongunstig en " de Commissie besloot dat de meest plausibele ICER (incremental cost-effectiveness ratio - incrementele kosteneffectiviteitsratio) voor bevacizumab in combinatie met paclitaxel ten opzichte van wekelijkse paclitaxel tussen £110,000 en £259,000 per gewonnen QALY schommelde" .